AR127518A2 - Anticuerpos anti-cd98 y usos de estos - Google Patents
Anticuerpos anti-cd98 y usos de estosInfo
- Publication number
- AR127518A2 AR127518A2 ARP220102971A ARP220102971A AR127518A2 AR 127518 A2 AR127518 A2 AR 127518A2 AR P220102971 A ARP220102971 A AR P220102971A AR P220102971 A ARP220102971 A AR P220102971A AR 127518 A2 AR127518 A2 AR 127518A2
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- antibodies
- conjugates
- antibody
- therapeutic
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 239000000032 diagnostic agent Substances 0.000 abstract 2
- 229940039227 diagnostic agent Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen anticuerpos anti-CD98 monoclonales y fragmentos de unión al antígeno de estos para suministrar un agente al cerebro de un sujeto que lo necesita. También se describen conjugados y construcciones de fusión que contienen el anticuerpo anti-CD98 o fragmento de unión al antígeno de este acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno de este, para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063006988P | 2020-04-08 | 2020-04-08 | |
US202063035961P | 2020-06-08 | 2020-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127518A2 true AR127518A2 (es) | 2024-01-31 |
Family
ID=78022989
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102971A AR127518A2 (es) | 2020-04-08 | 2022-10-31 | Anticuerpos anti-cd98 y usos de estos |
ARP220102972A AR127519A2 (es) | 2020-04-08 | 2022-10-31 | Anticuerpos anti-cd98 y usos de estos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102972A AR127519A2 (es) | 2020-04-08 | 2022-10-31 | Anticuerpos anti-cd98 y usos de estos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230174669A1 (es) |
EP (1) | EP4132974A4 (es) |
JP (1) | JP2023520811A (es) |
KR (1) | KR20220166304A (es) |
CN (1) | CN115698074A (es) |
AR (2) | AR127518A2 (es) |
AU (1) | AU2021253821A1 (es) |
BR (1) | BR112022020453A2 (es) |
CA (1) | CA3179922A1 (es) |
IL (1) | IL297143A (es) |
MX (1) | MX2022012633A (es) |
TW (1) | TW202142569A (es) |
WO (1) | WO2021205361A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024026471A1 (en) * | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2609016T3 (es) * | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
JPWO2011118804A1 (ja) * | 2010-03-26 | 2013-07-04 | 国立大学法人徳島大学 | 新規抗cd98抗体とその用途 |
AU2012340623A1 (en) * | 2011-11-23 | 2014-07-17 | Igenica Biotherapeutics, Inc. | Anti-CD98 antibodies and methods of use thereof |
CN107207591A (zh) * | 2014-12-10 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 血脑屏障受体抗体及使用方法 |
CN105385694B (zh) * | 2015-11-20 | 2019-01-18 | 中国人民解放军第四军医大学 | 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用 |
EP3468596A2 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2019246288A1 (en) * | 2018-06-22 | 2019-12-26 | Ossianix, Inc. | Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries |
-
2021
- 2021-04-07 IL IL297143A patent/IL297143A/en unknown
- 2021-04-07 WO PCT/IB2021/052892 patent/WO2021205361A1/en active Application Filing
- 2021-04-07 EP EP21783884.6A patent/EP4132974A4/en active Pending
- 2021-04-07 KR KR1020227038745A patent/KR20220166304A/ko active Search and Examination
- 2021-04-07 CA CA3179922A patent/CA3179922A1/en active Pending
- 2021-04-07 JP JP2022562042A patent/JP2023520811A/ja active Pending
- 2021-04-07 MX MX2022012633A patent/MX2022012633A/es unknown
- 2021-04-07 US US17/995,766 patent/US20230174669A1/en active Pending
- 2021-04-07 AU AU2021253821A patent/AU2021253821A1/en active Pending
- 2021-04-07 BR BR112022020453A patent/BR112022020453A2/pt unknown
- 2021-04-07 CN CN202180040974.0A patent/CN115698074A/zh active Pending
- 2021-04-08 TW TW110112657A patent/TW202142569A/zh unknown
-
2022
- 2022-10-31 AR ARP220102971A patent/AR127518A2/es unknown
- 2022-10-31 AR ARP220102972A patent/AR127519A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230174669A1 (en) | 2023-06-08 |
IL297143A (en) | 2022-12-01 |
CA3179922A1 (en) | 2021-10-14 |
JP2023520811A (ja) | 2023-05-19 |
AU2021253821A1 (en) | 2022-11-24 |
MX2022012633A (es) | 2023-01-11 |
KR20220166304A (ko) | 2022-12-16 |
WO2021205361A1 (en) | 2021-10-14 |
EP4132974A1 (en) | 2023-02-15 |
EP4132974A4 (en) | 2024-05-08 |
TW202142569A (zh) | 2021-11-16 |
CN115698074A (zh) | 2023-02-03 |
BR112022020453A2 (pt) | 2022-11-29 |
AR127519A2 (es) | 2024-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR127521A2 (es) | Composiciones y métodos para suministro a la barrera hematoencefálica | |
AR127519A2 (es) | Anticuerpos anti-cd98 y usos de estos | |
CO2021006092A2 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
BR112015010046A2 (pt) | Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino | |
Pastor et al. | Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers | |
Friedrich et al. | DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety | |
Monnier et al. | In vivo applications of single chain Fv (variable domain)(scFv) fragments | |
BR112014010383A2 (pt) | proteína de ligação a antígeno e uso do mesmo como produto direcionado a alvo para o tratamento de câncer | |
CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
RU2018139811A (ru) | Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
CR9236A (es) | Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas | |
BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
JP2015532102A5 (es) | ||
Gudjonsson et al. | Targeting influenza virus hemagglutinin to Xcr1+ dendritic cells in the absence of receptor-mediated endocytosis enhances protective antibody responses | |
CO6460768A2 (es) | Anticuerpos específicos para dkk-1 y sus usos | |
Zhou et al. | DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration | |
Ghaemi et al. | Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity | |
AR121802A1 (es) | Anticuerpos anti-cd98 y usos de estos | |
AR121803A1 (es) | Composiciones y métodos para suministro a la barrera hematoencefálica | |
BR112021017046A2 (pt) | Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos | |
MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. |